Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC

•Plasmacytoid urothelial carcinomas (UC) represent a rare and aggressive variant with poor outcome and a low sensitivity to chemotherapy.•Phenotypically, plasmacytoid UC seem to belong to the luminal subtype according to the molecular classification of urothelial bladder cancer.•Plasmacytoid UC show...

Full description

Saved in:
Bibliographic Details
Published in:Urologic oncology 2022-01, Vol.40 (1), p.12.e1-12.e11
Main Authors: Kossaï, Myriam, Radulescu, Camélia, Adam, Julien, Dziegielewski, Anaïs, Signolle, Nicolas, Sibony, Mathilde, Lebret, Thierry, Allory, Yves, Rouanne, Mathieu
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
B7-H1 Antigen - biosynthesis
Carcinoma, Transitional Cell - classification
Carcinoma, Transitional Cell - immunology
Carcinoma, Transitional Cell - metabolism
Carcinoma, Transitional Cell - pathology
CD8-Positive T-Lymphocytes
Female
Humans
Life Sciences
Male
Middle Aged
Molecular subtype
Plasmacytoid variant
Tumor-infiltrating lymphocytes
Urinary Bladder Neoplasms - immunology
Urinary Bladder Neoplasms - metabolism
Urinary Bladder Neoplasms - pathology
Urothelial carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Plasmacytoid urothelial carcinomas (UC) represent a rare and aggressive variant with poor outcome and a low sensitivity to chemotherapy.•Phenotypically, plasmacytoid UC seem to belong to the luminal subtype according to the molecular classification of urothelial bladder cancer.•Plasmacytoid UC show an inflamed tumor immune microenvironment and might benefit from immunotherapy. Plasmacytoid urothelial carcinoma (UC) is a rare pathological variant of UC with low chemotherapeutic sensitivity and dismal outcomes. The molecular and immune profiles of such tumors remain poorly investigated. Herein, we investigated the phenotypical features of a cohort of plasmacytoid UC (n=32) by comparison to a control group of conventional high-grade UC with matched clinicopathological characteristics (n=30). Histopathological analysis included the following antibodies: p63, GATA3, CK5/6, CK20 and HER2. In addition, the density of intra-tumor CD8+ lymphocytes, and PD-L1 expression in tumor (TC) and immune cells (IC) were evaluated. Plasmacytoid UC expressed GATA3 (97% vs 86% P=0.18), CK20 (59% vs 36% P=0.08) markers and showed a significantly higher rate of HER2 overexpression (2+ and 3+ score: 25% vs 0%, P
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2021.07.014